In-House Insights: Investment Diligence for a Healthcare VC

Edward Tung, legal counsel for Hong Kong-based venture capital firm ORI Capital, discusses the growing importance of ESG, the rise of special purpose acquisition companies (SPACs) and the advantage of having scientific expertise when representing healthcare and biotechnology companies.

6 minute readAugust 20, 2021 at 06:17 AM

Vincent Chow

In-House Insights: Investment Diligence for a Healthcare VC

Edward Tung, legal counsel at ORI Capital

Edward Tung is legal counsel, head of compliance and chair of the risk management committee for ORI Capital, a Hong Kong-based venture capital firm launched in 2015 that focuses on investing in innovative healthcare companies globally.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)